Phase 3 N=40 Gabapentin for Abstinence Initiation in Alcohol Dependence
Alcohol Dependence
Primary: Percent of Heavy Drinking Days Per Week — 22.5; 53.9 percent of heavy drinking days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=99 Alcohol Intervention for First Year College Students
Underage Alcohol Use
Primary: Acceptability-Number of Participants Who Found the Study Overall Favorable — 38; 0 Participants
Phase 2 N=150 ABT-436 for Alcohol Dependence
Alcohol Dependence · Alcohol Abuse · Alcohol Use Disorders
Primary: Weekly Percentage of Heaving Drinking Days — 37.6; 31.3 weekly percentage of heavy drinking days
N/A N=75 Clinical Intervention in Alcohol Use Disorder
Alcohol Use Disorder · Eligible to go Into the MRI Scanner · Short-term Abstinence From Alcohol Use (2 Week Abstinent)
Primary: Intervention Effects on Brain Functional Connectivity — 0.05; 0.19 percentage of Blood Oxygenation Level De
Phase 2 N=46 Varenicline to Reduce Alcohol Consumption in Heavy Drinkers
Alcohol Drinking
Primary: Alcohol Consumption — 92.0; 77.3 mg/%
N/A N=33 Alcohol Biosensor Monitoring for Alcoholic Liver Disease
Alcohol Use, Unspecified
Primary: Alcohol Use — 7.4; 5.3; 4.4 drinks per episode
Phase 3 N=300 ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence
Alcohol Dependence
Primary: Cumulative Percentage of Participants by Heavy Drinking Rate — 40.8; 47.3; 59.2; 59.5 percentage of participants — p=0.336
Phase 2 N=60 Do Treatments for Smoking Cessation Affect Alcohol Drinking?
Alcohol Drinking
Primary: Number of Drinks Consumed — 2.1; 2.05; 1.5; 1.7 number of drinks
Phase 2 N=49 Acamprosate to Reduce Symptoms of Alcohol Withdrawal
Alcohol-Related Disorders · Alcohol Dependence · Alcoholism
Primary: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 — 1.256772; 1.294178 Ratio of glutamate to creatine
Phase 4 N=41 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder
Alcohol Dependence · Anxiety Disorder
Primary: Treatment Adherence — 15 Participants
Phase 2 N=51 Medication Development in Alcoholism: Apremilast Versus Placebo
Alcohol Use Disorder
Primary: Craving to Drink — 33.84; 28.31 score on a scale — p=0.36
Phase 4 N=120 High Dose Vitamin B1 to Reduce Abusive Alcohol Use
Alcoholism
Primary: Change in Average Daily Alcohol Consumption — -3.4; -3.0 alcoholic drinks per day
Phase 2 N=200 Varenicline for Alcohol Dependence
Alcoholism
Primary: Weekly Percentage of Heavy Drinking Days — 37.9; 48.4 percentage of heavy drinking days
Phase 2 N=50 Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
Alcohol Use Disorder
Primary: Craving to Drink — 31.1; 33.2 score on a scale — p=.065
N/A N=103 Smoking Cessation in Alcoholics
Smoking Cessation · Alcohol Consumption
Primary: Number of Smoke-free Patients — 0; 3 participants — p==.111
Phase 3 N=60 Prometa Protocol for Alcohol Dependence
Alcohol Dependence
Primary: Percent Subjects Completely Abstinent — 44; 19; 33; 71 percent of participants — p=0.03
N/A N=122 PrEP and Alcohol - Enhancing HIV Pre-Exposure Prophylaxis (PrEP)
Hazardous Alcohol Use
Primary: Intervention Feasibility: Intervention Uptake — 122 Participants
Phase 2 N=120 Addressing Heavy Alcohol Use Consumption With Kudzu
Alcohol Use Disorder · Sexually Transmitted Diseases
Primary: Number of Binge Drinking Days — 2.15; 2.15; 1.94; 2.21 number of days
Phase 2 N=34 Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics
Alcoholism
Primary: Alcohol Craving Rating in Response to Saline Infusion — 1.704; 1.766 Units on a scale
Phase 2 N=64 Examining Alcohol Consumption, Perceptions, and User Experience of Alcohol Moderation Strategies
Alcohol Abuse · Alcohol Use Disorder · Alcohol Abuse, Episodic
Primary: The Young Adult Alcohol Consequences Questionnaire — -4.48; -4.63 outcome score minus baseline score
N/A N=120 Coping Skills for Alcohol Use
Alcohol Drinking · Coping Skills
Primary: Alcohol Use-Peak Drinks — 4.71; 4.79 number of drinks — p=>.05
Phase 3 N=75 Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
Bipolar Disorder · Alcoholism · Alcohol Abuse
Primary: Timeline Follow Back (TLFB) — -0.82; -0.71 drinks per drinking day
N/A N=23 Effects of a New Behavioral Intervention on Alcohol Craving and Drinking
Alcohol Drinking · Alcohol Drinking Related Problems
Primary: Change in Self-reported Alcohol Craving in the Laboratory Sessions — 11.7; 20.1; 15.3; 10.0 units on a scale
Phase 4 N=90 Acamprosate in Alcoholics With Comorbid Anxiety or Depression
Alcohol Dependence · Major Depression · Social Anxiety Disorder
Primary: Percent Days Drinking — 34.9; 31.9 percentage of days drinking — p=0.64
N/A N=37 Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
Phase 3 N=33 Varenicline Treatment for Active Alcoholic Smokers
Smoking · Tobacco Dependence · Alcohol Dependence
Primary: Prolonged Smoking Abstinence at End of 12 Weeks of Varenicline Treatment — 6; 1 participants — p=0.034
Phase 4 N=45 Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking
Smoking Cessation · Alcohol Drinking
Primary: Number of Participants Who Self-report Prolonged Abstinence From Smoking — 3; 0 Participants
Phase 2 N=32 Mifepristone for the Prevention of Relapses of Alcohol Drinking
Alcohol Use Disorders (AUD)
Primary: Number of Participants Experiencing Adverse Events in the Mifepristone Versus Placebo Group as a Measure of Safety and Tolerability — 0; 3 Participants — p=>.05
N/A N=77 Cognitive Retraining and Brain Stimulation for Alcohol Use
Binge Drinking
Primary: Drinks Per Drinking Day — 6.1; 6.8; 6.6; 7.5 drinks per drinking day
Phase 2 N=183 Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment
Substance Use Disorders · Alcohol Abuse · Alcoholism
Primary: Abstinence Rate (During the Preceding 90 Days) at 12 Months Follow-up Point as Assessed by the Form-90 — 40; 38; 47; 51 participants